Literature DB >> 2854841

Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy.

A S Basile1, S H Gammal, K D Mullen, E A Jones, P Skolnick.   

Abstract

The role of the GABA-benzodiazepine receptor complex in the pathogenesis of hepatic encephalopathy was investigated by recording the electrophysiological responses of single cerebellar Purkinje neurons from rabbits with hepatic encephalopathy due to galactosamine-induced fulminant hepatic failure. Both the GABAmimetic muscimol and the benzodiazepine receptor agonist flunitrazepam were 3-4 times more potent in depressing the spontaneous activity of Purkinje neurons from rabbits with hepatic encephalopathy than from control animals. Furthermore, qualitatively different responses of Purkinje neurons to benzodiazepine receptor antagonists (Ro 15-1788 and Ro 14-7437) were found in controls and rabbits with hepatic encephalopathy. These compounds markedly excited Purkinje neurons from rabbits with hepatic encephalopathy, but had either no effect (Ro 14-7437) or partially suppressed (Ro 15-1788) the spontaneous activity of neurons from control animals. In addition, incubation of Purkinje neurons from rabbits with hepatic encephalopathy with subthreshold concentrations of Ro 14-7437 reduced their sensitivity to muscimol, whereas treatment of control neurons with Ro 14-7437 had no effect on their sensitivity to muscimol. Finally, Purkinje neurons from hepatic encephalopathy and control rabbits displayed no difference in sensitivity to the depressant actions of the alpha-adrenoceptor agonist phenylephrine. These findings demonstrate a differential responsiveness of Purkinje neurons from an animal model of hepatic encephalopathy to ligands that interact with the GABA-benzodiazepine receptor complex. Furthermore, the observations made in this experimental model are consistent with the involvement of the GABA-benzodiazepine receptor complex in mediating hepatic encephalopathy, and provide a potential explanation for the reported efficacy of benzodiazepine receptor antagonists in ameliorating this syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854841      PMCID: PMC6569528     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  15 in total

Review 1.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

Review 3.  Endogenous GABAergic modulators in the pathogenesis of hepatic encephalopathy.

Authors:  J D Rothstein; M Olasmaa
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 4.  Effects of hyperammonemia on brain energy metabolism: controversial findings in vivo and in vitro.

Authors:  Arne Schousboe; Helle S Waagepetersen; Renata Leke; Lasse K Bak
Journal:  Metab Brain Dis       Date:  2014-03-01       Impact factor: 3.584

5.  Expression of Glutamate Decarboxylase (GAD) mRNA in the brain of bile duct ligated rats serving as a model of hepatic encephalopathy.

Authors:  Renata Leke; Themis R Silveira; Thayssa D C Escobar; Arne Schousboe
Journal:  Neurochem Res       Date:  2013-08-01       Impact factor: 3.996

Review 6.  Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

7.  Cortical benzodiazepine receptor binding in a rabbit model of hepatic encephalopathy: the effect of Triton X-100 on receptor solubilization.

Authors:  M Rössle; K D Mullen; E A Jones
Journal:  Metab Brain Dis       Date:  1989-09       Impact factor: 3.584

8.  Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

Authors:  J A Cossar; P C Hayes; R E O'Carroll
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

9.  Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil.

Authors:  H P Meyer; D A Legemate; W van den Brom; J Rothuizen
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

Review 10.  Flumazenil in the treatment of portal systemic encephalopathy--an overview.

Authors:  K Gyr; R Meier
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.